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Introduction
Anaplastic thyroid cancer (ATC) is rare, representing
2–14% of all thyroid cancers.1 It has very poor prog-
nosis, with the 5-year survival rate ranging from 1.0%
to 7.1% and median survival of 4–12 months.1,2
Nearly all the patients are elderly; peak incidence is 
in the seventh decade of life.3 The male-to-female ratio
is 1:1.5. The most common presentation in patients
with ATC is rapidly enlarging neck mass with a long-
standing history of goiter. Compressive symptoms,
such as hoarseness, dyspnea, cough and dysphagia,
are common, and 1-third of such patients have neck
pain. On examination, most patients have a dominant
mass measuring 5–10 cm in diameter, multiple other
nodules and enlarged cervical lymph nodes. Local
extension of tumor growth can be detected on sono-
graphy, computed tomography, magnetic resonance
imaging or scintigraphy. Diagnosis is established by
fine-needle aspiration cytology (FNAC) or by histo-
pathologic examination of the tumor after surgery. ATC
is very aggressive, such that cervical lymph nodes and
adjacent organs are frequently involved early. About
20–50% of patients have distant metastases, mostly to
the lung, bones, brain and liver.
Case Report
In 1989, a 68-year-old man visited our hospital because
he had an anterior neck mass which resulted in com-
pressive sensation over his throat and difficulty in
breathing. FNAC on the mass in another hospital had
shown normal thyroid follicular cells with lympho-
cytes. Thyroid function tests were within normal limits.
Except for mild elevation of thyroid stimulating hor-
mone receptor antibody (11%; normal, < 10% with
TBII-I), the thyroid antibodies were non-reactive.
There was no fever or leukocytosis. On physical exam-
ination, a nodule 2 × 2 cm in size was palpable over
the left lobe of the thyroid gland. It was stony hard,
smooth-surfaced, movable and non-tender. No lymph
node was found on the neck.
The patient received thyroid operation in April
1989. A large nodule about 5 × 3 × 4 cm in size, with
sternothyroid muscle invasion and 2 other small nodules
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were found in the left lobe of the thyroid. Frozen sec-
tion of enlarged lymph nodes in the neck showed
benign picture, but the specimen from the large thy-
roid nodule was reported as ATC. Total thyroidec-
tomy was performed. Microscopic examination showed
typical findings of ATC (Figures 1 and 2). No lymph
node involvement was noted, and the right lobe was
uninvolved.
Hyperfractionated accelerated radiotherapy with a
total dose of 6,000 cGy was given 30 times within 4
months. Human thyroglobulin (hTG) was < 3 ng/mL
after operation and radiotherapy. The patient was treated
with supraphysiologic dose of thyroxine. After opera-
tion, annual imaging studies showed negative findings
for residual disease. In serial follow-ups, hTG remained
undetectable and carcinoembryonic antigen levels were
within normal limits for many years. Unfortunately,
the patient died of pneumonia in a local hospital in
February 2000, more than 10 years after he was diag-
nosed with ATC.
Discussion
The prognosis of ATC depends on various factors, 
including age, tumor size, extent of disease, acute
symptoms, resectability and presence or absence of
distant metastases.4 Tumor size > 5 cm, distant meta-
stases, the presence of acute symptoms and leukocy-
tosis > 10,000/μL were suggested to be significant
risk factors in 1 study.5 Complete tumor resection was
the major favorable factor. Unfortunately, curative
resection for most cases of ATC is unlikely because
local extension has usually already occurred in most
cases at the time of diagnosis. ATC cannot uptake
iodine, so radioactive iodine ablation is not a helpful
therapy. External radiation may have some efficacy in
local disease control. Tennvall et al6 and Pollinger and
Duhmke7 commented that patients suffering from ATC
should receive combined treatment consisting of exten-
sive surgery, external irradiation with total doses up to
60 Gy, and chemotherapy.
Most patients with ATC die within 1 year of diag-
nosis. Although it is rare to have long-term survival,
Lam et al8 reported a 10-year survival rate of ATC in
Hong Kong Chinese of around 3%. In their report,
treatment with surgery was adopted as the first-line
treatment, followed by postoperative combination
chemotherapy and radiotherapy in selected patients.
Melliere et al9 reported 3 out of 22 ATC patients who
remained free of disease 10, 12 and 13 years, respec-
tively, after aggressive therapy. It was suggested that
complete tumor removal, followed by hyperfraction-
ated radiotherapy and other multimodal therapy might
result in long-term survival. In the case of our patient,
long-term survival may be attributed to early diagno-
sis, little adjacent structure invasion, no distant meta-
stasis, complete tumor resection and postoperative
irradiation.
Rodriguez et al10 reported a subgroup of ATC
coexisting with differentiated thyroid cancer, with
better prognosis than that for primary pure ATC.
However, there was no histologic evidence of differ-
entiated thyroid cancer in our case. Lam et al8 found
that the 10-year survival rate for patients with insular
carcinoma was 42%, which was 14 times higher than
that for ATC (3%). Insular carcinoma, a rare subtype
of thyroid cancer, has morphologic and biological
characteristics between well differentiated (papillary
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Figure 1. Anaplastic thyroid cancer with fascicular pattern of spin-
dle neoplastic cells (arrowheads) growing in a diffuse fashion with
follicular destruction (hematoxylin and eosin; 80×).
Figure 2. Anaplastic thyroid cancer with several giant tumor cells
with frequent mitotic figures and hyperchromatic nuclei representing
anaplastic change (arrowheads) (hematoxylin and eosin; 400×).
and follicular) and undifferentiated thyroid carcinomas
(anaplastic). Therefore, insular carcinoma is sometimes
mislabeled as ATC. A typical feature of insular carci-
noma is groups or islands of tumor cells (insulae) sur-
rounded by hypocellular fibrous tissue. The cells are
small and uniform in nature. On the other hand, ATC
is typically composed of varying proportions of spin-
dle, polygonal and giant cells. It usually has residual
elements of more differentiated thyroid cancer. In our
case, the histologic features were definitely diagnostic
for ATC. However, a few thyroid follicular structures
were found in the tumor, which implicates the possi-
bility of the ATC in this case being metaplasia from
thyroid follicular tissues.
Because of the dismal outcome of ATC, various new
therapeutic methods have been tried recently. Some of
them seemed to be effective in cellular experiments.11–14
Wang et al11 reported that a 3-hydroxy-3-methylglutaryl
coenzyme A reductase inhibitor could induce apopto-
sis and differentiation in ATC cells. Tumor necrosis
factor-α was also found to be able to induce differen-
tiation of human ATC cells through activation of
nuclear factor κB.12 These advances provide us with
some insights into the pathophysiology of ATC and
may be the dawning of a new era in the treatment of
this uncommon and terrible thyroid cancer.
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